Alessia P.
- Country
- Italy
- Department
- U.O. C. Dermatologia Clinica
Research Overview
- B7981040 - A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PLACEBOCONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY, SAFETY, AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO
- Long-term Safety Evaluation of Spesolimab in Patients with Hidradenitis Suppurativa Following Completion of Initial Spesolimab Treatment Phases
- Phase 3 Randomized Withdrawal and Dose-Up Titration Study of Ritlecitinib Tosilate in Adult and Adolescent Patients with Nonsegmental Vitiligo
Data & Insights
Has run more than one trial at 64 of 156 partner sites.
Specializations
Dermatological Conditions
This investigator specializes in the treatment of chronic inflammatory skin conditions, with particular emphasis on hidradenitis suppurativa and nonsegmental vitiligo.
- Moderate to Severe Hidradenitis Suppurativa
- Nonsegmental Vitiligo Management
The investigator's work encompasses innovative therapeutic approaches for these challenging dermatological conditions.
Therapeutic Innovation
The investigator explores novel treatment modalities including spesolimab, ritlecitinib, and AVTX-009 for dermatological applications.
- Targeted Immunological Therapies
- Long-term Treatment Strategies
- Novel Drug Development
Their research focuses on establishing optimal therapeutic protocols for chronic skin conditions.
Clinical Expertise
The investigator demonstrates particular interest in long-term disease management and treatment optimization for dermatological conditions.
- Treatment Efficacy Assessment
- Safety Profile Evaluation
- Therapeutic Response Monitoring
Their work encompasses both adult and adolescent patient populations requiring dermatological intervention.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.